Related references
Note: Only part of the references are listed.Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives
Irene Brusa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2022)
Targeting of Ubiquitin E3 Ligase RNF5 as a Novel Therapeutic Strategy in Neuroectodermal Tumors
Elisa Principi et al.
CANCERS (2022)
A small-molecule inhibitor and degrader of the RNF5 ubiquitin ligase
Jingjing Ruan et al.
MOLECULAR BIOLOGY OF THE CELL (2022)
Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment
Valeria Capurro et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
The preclinical discovery and development of the combination of ivacaftor plus tezacaftor used to treat cystic fibrosis
Lorenzo Guerra et al.
EXPERT OPINION ON DRUG DISCOVERY (2020)
Current development of CFTR potentiators in the last decade
Virginia Spano et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination
Guido Veit et al.
JCI INSIGHT (2020)
Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation
Drishti P. Ghelani et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Emerging Therapeutic Approaches for Cystic Fibrosis. From Gene Editing to Personalized Medicine
Iwona Pranke et al.
FRONTIERS IN PHARMACOLOGY (2019)
Adapting Proteostasis and Autophagy for Controlling the Pathogenesis of Cystic Fibrosis Lung Disease
Manish Bodas et al.
FRONTIERS IN PHARMACOLOGY (2019)
Ubiquitin ligase RNF5 serves an important role in the development of human glioma
Yong Gao et al.
ONCOLOGY LETTERS (2019)
Elexacaftor/Ivacaftor/Tezacaftor: First Approval
Sheridan M. Hoy
DRUGS (2019)
An overview on chemical structures as ΔF508-CFTR correctors
Virginia Spano et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2019)
Tezacaftor/Ivacaftor in Subjects with Cystic Fibrosis and F508del/F508del-CFTR or F508del/G551D-CFTR
Scott H. Donaldson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2018)
Ion Channel Modulators in Cystic Fibrosis
Martina Gentzsch et al.
CHEST (2018)
Cellular proteostasis: a new twist in the action of thymosin 1
Claudia Stincardini et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2018)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles
Dominic Keating et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia
Elvira Sondo et al.
CELL CHEMICAL BIOLOGY (2018)
Fatty Acid Cysteamine Conjugates as Novel and Potent Autophagy Activators That Enhance the Correction of Misfolded F508del-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
Chi B. Vu et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis
Luigina Romani et al.
NATURE MEDICINE (2017)
Tezacaftor-Ivacaftor in Residual-Function Heterozygotes with Cystic Fibrosis
Steven M. Rowe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR
C. E. Wainwright et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Genetic Inhibition Of The Ubiquitin Ligase Rnf5 Attenuates Phenotypes Associated To F508del Cystic Fibrosis Mutation
Valeria Tomati et al.
SCIENTIFIC REPORTS (2015)
Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation
Daniela De Stefano et al.
AUTOPHAGY (2014)
Discovery of N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide (VX-770, Ivacaftor), a Potent and Orally Bioavailable CFTR Potentiator
Sabine Hadida et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Functional architecture of the CFTR chloride channel
Paul Linsdell
MOLECULAR MEMBRANE BIOLOGY (2014)
Characterization of Biaryl Torsional Energetics and its Treatment in OPLS All-Atom Force Fields
Markus K. Dahlgren et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2013)
Mechanism-based corrector combination restores ΔF508-CFTR folding and function
Tsukasa Okiyoneda et al.
NATURE CHEMICAL BIOLOGY (2013)
CFTR: folding, misfolding and correcting the ΔF508 conformational defect
Gergely L. Lukacs et al.
TRENDS IN MOLECULAR MEDICINE (2012)
Regulation of ATG4B Stability by RNF5 Limits Basal Levels of Autophagy and Influences Susceptibility to Bacterial Infection
Ersheng Kuang et al.
PLOS GENETICS (2012)
Rescue of the mutant CFTR chloride channel by pharmacological correctors and low temperature analyzed by gene expression profiling
Elvira Sondo et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2011)
Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Defective CFTR induces aggresome formation and lung inflammation in cystic fibrosis through ROS-mediated autophagy inhibition
Alessandro Luciani et al.
NATURE CELL BIOLOGY (2010)
Mechanisms for Rescue of Correctable Folding Defects in CFTRΔF508
Diane E. Grove et al.
MOLECULAR BIOLOGY OF THE CELL (2009)
Chloride channels as drug targets
Alan S. Verkman et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770
Fredrick Van Goor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
The prevalence of cystic fibrosis in the European Union
Philip M. Farrell
JOURNAL OF CYSTIC FIBROSIS (2008)
Adapting proteostasis for disease intervention
William E. Balch et al.
SCIENCE (2008)
Increased expression of the E3 ubiquitin ligase RNF5 is associated with decreased survival in breast cancer
Kenneth D. Bromberg et al.
CANCER RESEARCH (2007)
RNF5, a RING finger protein that regulates cell motility by targeting paxillin ubiquitination and altered localization
C Didier et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator
MS Gelman et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Synthesis and antibacterial activity of new 1β-methylcarbapenems having the potential for intramolecular nonbonded S•••O interactions
Y Nagao et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2001)
Conformational and temperature-sensitive stability defects of the ΔF508 cystic fibrosis transmembrane conductance regulator in post-endoplasmic reticulum compartments
M Sharma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Identification of compounds with binding affinity to proteins via magnetization transfer from bulk water
C Dalvit et al.
JOURNAL OF BIOMOLECULAR NMR (2000)
Share Paper
